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Proton radiotherapy is a powerful tool in the local control of cancer. The advantages of proton
radiotherapy over gamma-ray therapy arise from the phenomenon known as the Bragg peak. This
phenomenon enables large doses to be delivered to well-defined volumes while sparing surrounding
healthy tissue. To fully realize the potential of this technique the location of the high-dose volume
must be controlled very accurately. An imaging system was designed and tested to monitor the
positron-emitting activity created by the beam as a means of verifying the beam’s range, monitoring
dose, and determining tissue composition. The prototype imaging system consists of 12 pairs of
cylindrical BGO detectors shielded in lead. Each crystal was 1.9 cm in diameter, 5.0 cm long, and
separated by 0.5 cm from other detectors in the row. These are arranged in two rows, 60 cm apart,
with the proton beam and tissue phantoms half-way between and parallel to the detector rows.
Experiments were conducted with 150 MeV continuous and macro-pulsed proton beams which had
beam currents ranging from 0.14 nA to 1.75 nA. The production and decay of short-lived isotopes,
15O and 14O, was studied using 1 min irradiations with a continuous beam. These isotopes provide
a significant signal on short time scales, making on-line imaging possible. Macro-pulsed beams,
having a period of 10 s, were used to study on-line imaging and the production and decay of
long-lived isotopes, 13N, 11C, and 18F. Decay data were acquired and on-line images were obtained
between beam pulses and indicate that range verification is possible, for a 150 MeV beam, after one
beam pulse, to within the 1.2 cm resolution limit of the imaging system. The dose delivered to the
patient may also be monitored by observing the increase in the number of coincidence events
detected between successive beam pulses. Over 80% of the initial positron-emitting activity is from
15O while the remainder is primarily 11C, 13N, 14O with traces of 18F, and 10C. Radioisotopic
imaging may also be performed along the beam path by fitting decay data collected after the
treatment is complete. Using this technique, it is shown that variations in elemental composition in
inhomogenous treatment volumes may be identified and used to locate anatomic landmarks. Ra-
dioisotopic imaging also reveals that 14O is created well beyond the Bragg peak, apparently by
secondary neutrons. © 1999 American Association of Physicists in Medicine.
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Proton and light-ion radiotherapy are increasingly important
tools for treating tumors due to the sharp rise and fall of dose
at the end of the ions range. This advantage over other ra-
diotherapy modalities is limited in many situations by the
inability to directly monitor the dose delivered to the tumor
volume. The depth of the maximum dose is dependent on the
beam energy, tissue composition, multiple Coulomb
scattering,1 and in particular the inhomogeneities along the
beam path.2–4 This makes it very difficult to determine the
precise range of the treatment beam. The introduction of
x-ray CT in treatment planning greatly improved dose local-
ization. However, it has been shown that in the presence of
bone or air gaps along the beam path, CT range estimates
may be in error by more than 10%.5,6 Thus it is desirable to
develop on-line, in vivo techniques for imaging induced ac-
tivity, to help ensure that the lethal dose is localized within
the prescribed tumor volume.992 Med. Phys. 26 6, June 1999 0094-2405/99/266Tissue activation was first discussed in detail by Tobias in
19497 and was first reported in gamma-ray experiments by
Mayneord et al. later that year.8 Since then the radioactivity
induced in tissues by photon,8–10 proton,11,12 neutron,13
pion,14–16 and heavy-ion radiotherapy beams17–19 has been
investigated. This induced activity has been studied as a
source of patient dose,11,20,21 as a means of determining el-
emental tissue composition,10,11,13 and for determining dose
distributions.14,15,17,22–31 In vivo dose localization by imaging
positron-emitting nuclei is considered essential for light-ion,
and radioactive-ion beam therapy.30 Investigations of PET as
a monitor for proton radiotherapy beams generally indicate
that it is capable of measuring useful dosimetric, composi-
tional, and range information.11,12,22,25–29,31 However, many
of these experiments were conducted off-line by detection
systems in the vicinity of the treatment beam requiring that
the phantoms or subjects under study be moved. The result-
ing images predominantly show activity from radioisotopes992/992/15/$15.00 © 1999 Am. Assoc. Phys. Med.
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tation and setup time. While these studies lend valuable in-
sight, the images obtained are mainly of 11C. Because 11C is
produced in relatively small amounts and has a 20 min half-
life, the images obtained tend to have poor statistics and
require an uncomfortably long imaging time for the patient.
In contrast, 15O is the most abundant positron-emitting iso-
tope produced during proton radiotherapy due to the abun-
dance of oxygen in the body, its short 2 min half-life, and the
relatively large cross section of the 16O(p ,pn)15O reaction.32
Therefore, statistically significant images of 15O may be ob-
tained in seconds or minutes. Such images are useful for
on-line range verification, studying the elemental composi-
tion of the tissue along the beam path, and studying blood
flow within the tumor, all of which may have an impact on
subsequent treatment planning and delivery.
In this work we present the measurements of the spatial
and temporal distributions of positron-emitting activity cre-
ated in tissue by continuous and pulsed proton beams at en-
ergies near 150 MeV. These measurements were made using
a prototype imaging system designed for these preliminary
investigations. The goals are: ~i! to determine if such a sys-
tem may be used as an accurate on-line range monitor be-
tween beam pulses; ~ii! quantify the temporal and spatial
activity distributions of the various PET isotopes; ~iii! deter-
mine if tissue composition may be ascertained from the iso-
topic activity distributions for the purpose of improving sub-
sequent treatment planning and delivery; and ~iv! investigate
the possibility of using such a system to monitor dose.
II. MATERIALS AND METHODS
In the following sections we describe the proton beam and
tissue phantoms used during the experiments and give a brief
description of the imaging system. We then present the algo-
rithms used to separate, reconstruct, and quantify the depth-
distributions for each of the major positron-emitting isotopes
produced in experiments where decay data were collected.
This is followed by a description of the continuous and
macro-pulsed beam experiments conducted.
A. Characteristics of the proton beam
A beam of protons was produced at the National Super-
conducting Cyclotron Laboratory at Michigan State Univer-
sity ~NSCL! using a K1200 isochronous cyclotron. The pri-
mary beam of ionized molecular hydrogen was accelerated
with rf frequencies of 24.1036 MHz which produced a
micro-pulse structure in the beams. The beam then passed
through a stripping foil to dissociate the molecular bond and
produce free protons which were then focused to an average
FWHM diameter of 1 cm. After passing through a 0.0254 cm
thick Havar vacuum window and into air, the beams entered
the phantoms at 150 MeV.
B. Tissue phantoms
The 535327 cm3 tissue phantoms were placed with their
long dimension along the axis of the proton beam. The beam
entered the phantom through the center of one of the 5Medical Physics, Vol. 26, No. 6, June 199935 cm2 faces of the sample. This provided ample pathlength
to stop the 150 MeV proton beam, whose range was 16.0 cm,
in the phantom. This also provided a significant amount of
tissue beyond the Bragg peak to observe any production of
PET isotopes by neutron activation beyond the Bragg peak.
Most tissue-equivalent materials have electron densities
similar to those of human tissues. However, for these experi-
ments it was necessary to use a phantom with the correct
isotopic composition, thus providing activity distributions
similar to those which would be produced in human tissue.
The elemental composition of the swine-tissue phantoms
used for these experiments are shown in Table I, along with
the composition of human muscle and adipose tissue for
comparison. The most abundant elements in tissue from
which positron-emitting isotopes may be produced are oxy-
gen, carbon, and nitrogen ~see the Appendix!. The phantoms
were placed and irradiated along the axis of a prototype on-
line monitoring system which was used to monitor the
positron-emitting activity produced.
C. The on-line imaging system
The g-ray detection system used consisted of two rows of
BGO detectors as shown in Fig. 1. Each row contained 12
detectors. Each BGO detector measured 1.91 cm in diameter
by 5.08 cm long and was separated from its neighbor by 0.51
cm. The front surfaces of the detectors between the two rows
were separated by 60 cm.
Both rows of detectors were encased in custom-made lead
shields to reduce background radiation and to suppress de-
tection of Compton scattered g’s and b2’s between crystals.
In addition, lead shutters provided shielding to the front of
the detectors while the beam was on to avoid activation of
the crystals. These shutters were operated by a pneumatic
cylinder which was controlled by a variable time delay relay
switch. A photogate mounted on the shutters controlled the
phase of the rf to the cyclotron so the beam would be off
when the shutters were open.
The detectors in one row were placed in coincidence with
the detectors in the other row, resulting in 144 possible de-
tector combinations for detecting positron decay events.
However, many of the detector pairs monitor the same re-
gion along the beam path resulting in 23 unique monitored
TABLE I. Elemental tissue compositions by percent mass.
Element Swine Muscle Adipose
Oxygen 74.61 72.893 27.8
Hydrogen 9.80 10.2 11.4
Carbon 11.32 12.3 59.8
Nitrogen 2.52 3.5 0.7
Sulfur ,0.5 0.5 0.1
Chlorine fl fl 0.1
Potassium 0.29 0.3
Phosphorus 0.27 0.2
Sodium 0.21 0.08 0.1
Magnesium 0.065 0.02
Calcium 0.022 0.007
Iron 0.0034 fl
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the 12 opposing detector pairs plus the 11 positions between
neighboring detector pairs. The number of coincidence
events detected in each of these 23 unique positions, due to a
positron decay distribution, D, constitutes the vector re-
sponse, R of the system. The mapping between the two rep-
resentations is provided by the system matrix, S, which is
measured during the calibration process.
The system matrix is formed by moving a calibrated
positron-emitting source along the system axis and recording
the response vector, R, over each of the 23 unique positions.
These response vectors are then placed beside each other in
columns to form the system matrix. The matrix characterizes
the solid angle, efficiency, detection probability, and acci-
dental coincidence probability of the detection system at
each of the 23 unique positions monitored by the 12 detector
pairs. The total length of the system is 28.4 cm, conse-
quently, each of the 23 resolvable positions is approximately
1.2 cm in length. The imaging system has been described in
greater detail in other works.33–35
D. Image reconstruction and isotopic imaging
The general image reconstruction algorithm for the sys-
tem has been discussed in Ref. 33. Here we present the tech-
nique used to image individual radioisotopes produced in the
field of view. The proton beam creates a distribution of PET
activity, A(r,t), as given by Eq. ~A5!. Over the image ac-
quisition time, TI5t22t1 , the spatial distribution of decays
is
D~r!5E
t1
t2A~r,t !dt . ~1!
This vector distribution of decays produces a vector re-
sponse, R, from the imaging system. The vector response
must be corrected for attenuation within the object to make
quantitative measurements. In the results presented here, this
was accomplished by calculating the pathlength through the
phantom for each detector pair. Objects with more compli-
cated geometries may require transmission studies with a
FIG. 1. Prototype on-line imaging system.Medical Physics, Vol. 26, No. 6, June 1999calibration source to obtain attenuation corrections. The
mapping between the vector response and the spatial decay
distribution is given by the system matrix, S.33 The spatial
decay distribution is given by
Dabs5
1
m
S AcalLns DS21R, ~2!
where Acal is the activity of the calibration source in decays
per second, L is the length of the imaging array, ns is the
velocity of the calibration source, m is the number of ele-
ments in the reconstructed decay distribution, and S21 is the
inverse of the system matrix. During on-line imaging, data
were acquired between beam pulses. In these experiments
the image acquisition time was typically 5 s which is half the
beam period, TI5T/2. After each beam pulse, the expected
decay distribution based on Eqs. ~A4! and ~A5! may be com-
pared with that found by Eq. ~2!.
Different isotopes may be imaged if a series of datasets
are acquired during the decay of the activity distribution.
This ‘‘radioisotopic imaging’’ is particularly useful for de-
termining the distribution of oxygen along the beam path
since the 16O(p ,n)15O reaction is the only significant source
of 15O in soft tissues and bone. The total imaging time
should be about three times the half-life of the radioisotopes
being examined, or 5 to 6 min in the case of 15O, to obtain
the most events in the shortest amount of time and ad-
equately sample the decay curve of interest.
Suppose the decaying activity distribution is continuously
sampled by recording the response vectors in a series of time
increments of length, TI5t22t1 . In any given element of
one of the response vectors, the number of counts is propor-
tional to the sum of the isotopic activities at the observed
position and has the form
Dj}E
t1
t2F(
i
Aimaxe2l ilGdt ,
~3!
Dj}(
i
AimaxS e2l iTl21l i D e2l it2.
The sequential decay data recorded for each element of the
response vector may be fit to a decay model to find the initial
distribution of activity, Aimax , for each isotope in response
space. Statistical tests for determining the presence of trace
radioisotopes in the decay data are presented in the next sec-
tion. Once the initial activity of each radioisotope has been
determined, the total number of counts occurring in that el-
ement of the response vector due to a specific radioisotope
may be found by integrating the decay curve with the appro-
priate constants. In this way isotopic response vectors may
be obtained for each radioisotope occurring in the field of
view of the imaging system. Radioisotopic images may then
be found by using Eq. ~2! with each of the radioisotopic
response vectors.
E. Error analysis and statistical tests
The uncertainty in a reconstructed image may be found
using the following theorem:36
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with positive definite covariance matrix K and mean
vector m. Let S be a nonsingular linear transformation
in n dimensions. Then R5SD is an n-dimensional nor-
mal random vector with covariance matrix Q
5SKST. . .’’
The covariance matrix, Q, of the response vector, R, con-
tains the variance of the elements of R on its diagonal with
all other elements of Q being zero. The uncertainty in the
elements of R is Poisson so that Q j j5Rj . The counting of
radioactive isotopes is also a Poisson process, therefore the
variance in the elements of the reconstructed image is given
by the diagonal elements of the covariance matrix, K, where
K is given by
K5S21Q~ST!21. ~4!
The uncertainties in radioisotopic images are compounded
by the uncertainty in determining the initial activity coeffi-
cients while fitting the decay data. The decay curves are fit
using the Levenberg–Marquardt method with Poisson
weighting. While this nonlinear fitting algorithm may be
used to determine the half-lives of unknown radioisotopes,
the half-lives of the isotopes produced in tissue are well
known. In this study only the linear activity coefficients are
included in the decay model while the half-lives are fixed.
This algorithm calculates the covariance matrix for the fit
parameters, giving an estimate of the uncertainty in each of
the initial isotopic activities for each element of the response
vector. The calculated variance is larger than the variance
expected from Poisson counting statistics alone and also in-
cludes the variance in the fit. It is thus possible to form
response variance vectors, V, for each decaying radioisotope
by integrating the decay curve with the appropriate con-
stants. As described above, the covariance matrix for a given
isotopic response vector is then Q j j5Vj .
The decay data from an experiment using a tissue phan-
tom will predominately contain 11C, 13N, and 15O, but other
positron-emitting isotopes such as 10C and 14O may be pro-
duced in smaller quantities. If the decay data from each of
the 23 resolvable elements are summed, the statistics may be
sufficient to estimate the abundances of these radioisotopes
by including them in the fit to the summed decay data. Two
statistical tests, based on the F-distribution, are used to vali-
date the inclusion of trace radioisotopes in the decay model
during a fit.37 The first is an F test of the multiple-correlation
coefficient, R, and verifies that the fit coefficients are posi-
tive and tests the minimum square deviation of the data from
the decay model. The second F test compares two decay
models which differ by one term, that of the trace radioiso-
tope in question. The latter test is based on the difference in
the chi-squares of the two decay models. The presence of the
trace radioisotope in question may then be verified to the
desired level of confidence, which in this work is set at 99%.
More details on these tests may be found in Ref. 37.
When the decay data from each of the resolvable elements
are not summed, the statistics may not be sufficient to iden-
tify the trace radioisotopes present in any one of the ob-Medical Physics, Vol. 26, No. 6, June 1999served segments along the system axis. The above tests are
applied to obtain the optimal fit for each position. If the
presence of the trace radioisotopes cannot be confirmed by
the F tests at the 99% confidence level, the trace radioisotope
activity coefficients are set to zero. Measurements of the
background rates in the imaging system resulted in vanish-
ingly small rates. F tests on the inclusion of a background
term in the decay model indicate that it generally does not
improve the fit of the data to the model. Including terms for
background or trace radioisotopes in the decay model at sig-
nificantly lower confidence levels introduces additional lin-
ear correlations among the isotopic activity coefficients
which degrades the quality of the isotopic images.
F. Continuous proton beam into a tissue phantom
Using the materials and techniques described above, the
production and distribution of short-lived isotopes was stud-
ied using a continuous beam. The activity was created by a
150 MeV proton beam with a current of 1.75 nA and an
expected range of 16.0 cm in tissue. This beam was im-
planted continuously for 1 min into a swine-tissue phantom.
The spatial and temporal decay distributions were measured
beginning immediately after the beam was turned off. The
surface of the 535327 cm3 phantom was placed 2.0
60.3 cm from the front end of the detector array, inside the
imaging system on the systems axis. The beam was termi-
nated by opening the shutters, which dephased the accelerat-
ing rf and enabled data acquisition. Decay data were col-
lected for 57 min in 10 s bins. The initial coincidence rate
was 2322 Hz with the computer being live for 2308 of these
events giving an acquisition livetime of 99.4%. The total
number of coincidence events recorded was 9.073105 with
7.923105 of these meeting the required timing and energy
window cuts. The initial singles rates in each of the 24 de-
tectors, after the beam was turned off, ranged from 3500 Hz
to 6700 Hz.
G. Macro-pulsed proton beams into tissue phantoms
Variable macro-pulse periods were achieved by phasing
and dephasing the rf to the cyclotron dees in synchronization
with the pneumatically controlled shutter system on the im-
aging system. The period of the shutters was controlled by a
variable time delay relay switch. A photogate mounted on
the shutters controlled the phase of the rf to the cyclotron so
the beam would be off when the shutters were open. Typical
periods for a shutter cycle were 10 s.
The feasibility of imaging between beam macro-pulses
was investigated by performing experiments using a 150
MeV proton beam with a current of 1.75 nA, macro-pulsed
with a 10 s period. This beam was implanted into a tissue
phantom for 2 min resulting in 12, 5 s beam pulses being
delivered to the phantom. Data were acquired for 5 s be-
tween each of the 12 beam pulses and in 10 s bins for 56 min
after beam delivery. A swine-tissue phantom was placed
with its front surface 6.060.3 cm inside the imaging system.
Another pulsed-beam experiment was conducted to inves-
tigate the maximum activity produced with pulsed beams for
996 Litzenberg et al.: On-line monitoring of radiotherapy 996radioisotopes with half-lives comparable to or shorter than
the treatment time. In this experiment a 0.14 nA beam with a
20 s period was implanted into a tissue phantom for 21 min.
Data were acquired for 10 s between beam pulses and con-
tinued for an additional 61 min after the beam ended. The
front surface of the 535327 cm3 swine-tissue phantom was
placed 2.060.3 cm inside the front end of the imaging sys-
tem.
III. RESULTS
The following sections contain the results of several im-
aging experiments carried out using continuous and pulsed
protons beams implanted into tissue phantoms. Decay data
were collected for the three experiments presented. In each
case, images are presented based on the cumulative dataset
and based on the isotopic imaging technique described ear-
lier. These are compared with the expected decay distribu-
tions as calculated using the reaction cross sections shown in
Figs. 2~a! and 2~b! and the composition shown in Table I
FIG. 2. ~a! Cross sections for nuclear reactions leading to the production of
positron-emitting materials. ~b! Cross sections for nuclear reactions leading
to the production of positron-emitting materials.Medical Physics, Vol. 26, No. 6, June 1999which is assumed to be uniform. In the case of macro-pulsed
beams, images acquired between beam pulses are presented.
A. Continuous proton beams into a tissue phantom
Figure 3 shows the sum of the decay data from the 23
positions, the fit to the decay data, and the residuals which
are shown at the top with the Poisson uncertainty. The best
fit to the decay data is obtained by including 15O, 14O, 13N,
11C, and 10C. The F tests for a decay model including 14O
and 10C indicate both are present at a 99% confidence level
in the summed decay data. However, including a background
term is not justified by these tests and this coefficient was set
to zero. The isotopic response vectors shown in Fig. 4 were
produced by first fitting the decay data to the above decay
model for the individual ‘‘pixels.’’ The validity of including
the 10C term in the decay model was tested for each set of
decay data but was not justified at the 99% confidence level
for any of the pixels. Figure 4 shows the cumulative and
radioisotopic response vectors integrated over the imaging
FIG. 3. The total decay data collected while imaging after a 1.75 nA, 150
MeV proton beam was implanted for 60 s. The fit to the data shows that 15O,
14O, 13N, 11C, and 10C are present at the 99% confidence level. The residuals
of this fit are shown at the top with the Poisson uncertainty.
FIG. 4. Radioisotopic response vectors generated from decay data.
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are the square root of the elements of the variance vectors,
AVj, described above. The error bars were omitted for the
14O and 13N response vectors for illustrative purposes but are
comparable to the others shown. Figure 5 shows the ex-
pected activity distribution where different reactions leading
to the same radioisotope have been added. The radioisotopic
image vectors, shown in Fig. 6, were calculated using Eq.
~2!. The range of the 150 MeV proton beam is 16.0 cm in
tissue and is well determined within the resolution of the
imaging system. The distribution of activity drops abruptly
near the end of the proton beams range as the proton energy
falls below the threshold energies of the various nuclear re-
actions. However, some slight but significant 14O activity is
observed beyond this range.
Table II gives the activity expected for each reaction, the
expected total activity; and number of decays, while imag-
ing, by radioisotope, and the total number of decays as de-
FIG. 5. Expected isotopic decay distribution for a 1.75 nA, 150 MeV proton
beam implanted for 60 s.Medical Physics, Vol. 26, No. 6, June 1999termined from the reconstructed isotopic images. The uncer-
tainties given with the experimentally determined values
only reflect the uncertainties due to counting statistics and
fitting the data to the decay model. The uncertainty in the
beam current during the experiments was about 20%. ~Dur-
ing an actual treatment the beam current would be monitored
to a much higher precision using a transmission ionization
chamber.! Given these uncertainties, the abundance and dis-
tribution of 11C of 15O agree well with the expected distribu-
tions. However, based on the known tissue composition, the
amount of 13N observed is almost twice as large as expected
and the observed amount of 14O is over 17 times the ex-
pected amount.
B. Pulsed proton beams into a tissue phantom
The production and decay of the activity resulting from a
2 min macro-pulsed beam with a 10 s period is shown in Fig.
7. As expected, the number of coincidences detected between
FIG. 6. Radioisotopic images of the decay distributions of activity created by
a 1.75 nA, 150 MeV proton beam implanted for 60 s.TABLE II. Summary of the isotopic activities produced and the expected and measured number of total coinci-
dence events. This activity was produced by a 1.75 nA, 150 MeV proton beam which was implanted into a
swine-tissue phantom continuously for 60 s.
Reaction
Expected
activity ~mCi!
by reaction
Expected
activity ~mCi!
by isotope
Expected
counts (3109)
by isotope
Measured
counts (3109)
by isotope
16O(p ,3p4n)10C 94.0 94.0 0.097
12C(p ,pn)11C 52.0
14N(p ,a)11C 2.6 107.8 5.8 5.7460.08
16O(p ,apn)11C 53.2
14N(p ,pn)13N 4.4 43.3 1.3 2.7460.09
16O(p ,a)13N 38.9
14N(p ,n)14O 1.1 42.9 0.162 2.9160.09
16O(p ,p2n)14O 41.8
16O(p ,pn)15O 1877.5 1877.5 12.25 12.3160.11
18O(p ,n)18F 0.0023 0.0023
Totals 2248.8 19.61 23.7060.19
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diation time on short time scales. During a patient treatment,
verifying the range of the beam early in the treatment is of
primary importance. Ideally, using a macro-pulsed beam, the
range could be measured after one pulse with the continua-
tion of the treatment being contingent upon verification of
the proper range. Figure 8 shows the reconstructed image
after one macro-beam pulse. This image was reconstructed
from 1431 coincidence events. The expected dose distribu-
tion is shown for comparison. The uncertainties in the image
produced after one pulse are large, nonetheless the number of
events is adequate for range verification.
Inspection of the inside of the swine-tissue phantom re-
vealed a small adipose deposit beginning 11.260.1 cm from
the surface of the phantom. Its spatial extent along the beam
path was 0.460.1 cm. The elemental composition of this
material was assumed to be similar to that given in Ref. 38
FIG. 7. The total decay data collected while imaging after a 1.75 nA, 150
MeV proton beam with a 10 s pulse period was implanted for 120 s. Statis-
tical tests of the decay model show that 15O, 14O, 13N, 11C, and 10C are
present at the 99% confidence level. The residuals of this fit are shown at the
top with the Poisson uncertainty.
FIG. 8. Range verification using the reconstructed decay distribution after
one macro-beam pulse. This distribution was reconstructed from 1431 co-
incidence events. The expected dose distribution is shown for comparison.Medical Physics, Vol. 26, No. 6, June 1999and is shown in Table I. The decay distribution of positron-
emitting activity, given this phantom geometry and compo-
sition, is shown in Fig. 9. The presence of the adipose tissue
changes the range of the beam by a small amount which is
well below the resolution of the imaging system. Conse-
quently, we do not experimentally observe a deviation in the
proton range as might be expected. The decay distribution in
Fig. 9 shows a slightly larger number of decays from the
adipose region. This is due to the long half-life of 11C and
the long, 56 min, imaging time. The initial amount of 15O
activity in this adipose region is about half that of regions
containing muscle tissue due to the differing oxygen content.
As in the experiments with continuous beams, 15O, 14O,
13N, 11C, and 10C are present in the summed decay data at
the 99% confidence level. Radioisotopic response vectors
were produced by first fitting the decay data to a decay
model containing these radioisotopes for the individual pix-
els. Again, the validity of including the 10C term in the decay
model was tested for each set of decay data but was not
justified at the 99% confidence level for any of the pixels.
The isotopic images are shown in Fig. 10. Note the dip in the
FIG. 9. Expected isotopic decay distribution over 56 min for the activity
created by a 1.75 nA, 150 MeV proton beam with a 10 s period which was
implanted in a tissue phantom for 120 s. The dose distribution for a
monoenergetic beam is shown for range comparison.
FIG. 10. Radioisotopic images of the decay distributions of activity created
by a 1.75 nA, 150 MeV proton beam with a 10 s period which was im-
planted in a tissue phantom for 120 s.
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Medical Physics, VTABLE III. Summary of the isotopic activities produced and the expected and measured number of total
coincidence events. This activity was produced by a 1.75 nA, 150 MeV proton beam which was pulsed with a
10 s period and implanted into a swine-tissue phantom for 120 s.
Reaction
Expected
activity ~mCi!
by reaction
Expected
activity ~mCi!
by isotope
Expected
counts (3109)
by isotope
Measured
counts (3109)
by isotope
16O(p ,3p4n)10C 56.2 56.2 0.058
12C(p ,pn)11C 57.1
14N(p ,a)11C 2.5 110.9 6.15 5.7060.06
16O(p ,apn)11C 51.3
14N(p ,pn)13N 4.2 41.3 1.29 2.2860.07
16O(p ,a)13N 37.1
14N(p ,n)14O 0.85 33.6 0.13 1.6160.07
16O(p ,p2n)14O 32.7
16O(p ,pn)15O 1597.6 1597.6 10.42 10.1960.09
18O(p ,n)18F 0.002 36 0.002 36
Totals 1910.1 18.05 19.7860.1515O distribution and the rise in the 11C distribution due to the
adipose deposit in the thirteenth resolvable element. Table III
gives the total activity expected for each reaction, the ex-
pected total activity by radioisotope, and the expected and
measured number of decays by radioisotope. The uncertainty
in the expected activities given in Table III due to the uncer-
tainty in the beam current is 20%. The amount of 15O and
11C agree well within these uncertainties. However, the
amount of 13N is 77% larger than expected and the amount
of 14O is 12.4 times larger than expected.
C. Activity saturation with macro-pulsed beams in
tissue
The production of PET activity due to a large number of
pulses, and subsequent decay, is shown in Fig. 11, where
time zero corresponds to the end of the irradiation. The pro-
duction of activity is relatively constant over the first 2–3
min of irradiation while the abundance of 15O is still low.
The sudden decrease in the number of counts between pulses
which occurs at 2500 s is due to small variations in the
response time of the shutter system relative to that of the data
acquisition system. It can be seen that after 20 min the pro-
duction rate has slowed considerably as all isotopes decay
almost as quickly as they are produced. Since the beam du-
ration is comparable to the half-life of 11C, 20 min, and 13N,
10 min, the activity of these isotopes will not be at their
maximum levels. The activities of isotopes with half-lives
shorter than roughly 5 min, such as 15O and 14O, should be
near their maximum levels. The decay data shown in Fig. 11
was fit and found to contain primarily 15O, 13N, 11C, and
some 14O. 10C is not present at the 95% confidence level in
the summed decay data. Again, while 14O is present at the
99% confidence level in the total decay data, it was not
found at this level in any of the individual positions. Fitting
for 15O, 13N, and 11C and reconstructing their decay distri-
butions gives the radioisotopic images shown in Fig. 12. Theol. 26, No. 6, June 1999expected activity distributions, where different reactions
leading to the same radioisotope have been added, are shown
in Fig. 13. Note that under the given beam and imaging
parameters, the number of decays from 11C is greater than
from 15O. This is due to the 21 min beam duration. Table IV
gives the total activity expected for each reaction, the ex-
pected total activity by radioisotope, and the expected and
measured number of decays while imaging by radioisotope.
Again, the uncertainty in the total expected activity and ex-
pected counts by isotope is about 20% due to the uncertainty
in the beam current. As before, the measured amounts of 11C
and 15O agree with the expected amounts but the measured
amount of 13N is twice as high as expected.
FIG. 11. The total decay data collected while imaging after a 0.14 nA, 150
MeV proton beam with a 20 s pulse period was implanted for 23 min.
Statistical tests of the decay model shows that 15O, 14O, 13N, and 11C are
present at the 99% confidence level. The fit to the decay data using this
model is shown by the solid line and the residuals of this fit are shown at the
top with the Poisson uncertainty.
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A. Imaging system design
It has been shown that the range of a proton therapy beam
can be verified on-line within the resolution of the imaging
system and some information on composition can be ob-
tained. However, several issues still need to be addressed. To
be optimal for clinical use the resolution of the imaging sys-
tem must be reduced to the subcentimeter range. In design-
ing a detection system to accomplish this, consideration must
be given to the average coincidence detection efficiency per
unit length along the system axis. To maintain sufficient ef-
ficiency to obtain statistically significant images, the detector
height perpendicular to the plane of the detector array would
have to increase if the width of each detector is decreased.
This increase in detector volume would also increase the
chance coincidence rate, especially if multiple crystals are
optically coupled and fewer PMT’s used for readout. How-
FIG. 12. Radioisotopic images of the decay distributions of 15O, 13N, and
11C activity created by a 0.14 nA, 150 MeV proton beam with a 20 s period
which was implanted in a tissue phantom for 23 min.Medical Physics, Vol. 26, No. 6, June 1999ever, the detector volume could be reduced by shortening the
length of the BGO crystals from 5 cm to 3 cm with little loss
of detection efficiency. Further design considerations and
suggested improvements for on-line PET isotope monitoring
devices may be found in Ref. 33.
B. Nuclear secondaries and the production of 14O
The discrepancies noted above, between the amount of
14O expected and the amount observed, may arise from at
least two different sources. The calculated and experimental
cross sections used to calculate the production of 14O have
some uncertainty39,40 and 14O may be produced in nuclear
reactions induced by secondary particles such as neutrons.
The cross sections used to calculate the amount of 14O cre-
ated by the 16O(p ,p2n)14O reaction were calculated using
the GNASH code system.41 These calculated cross sections are
about a factor of 2 smaller than experimental values which
FIG. 13. Expected isotopic decay distribution over 61 min for the activity
created by a 0.14 nA, 150 MeV proton beam with a 20 s period which was
implanted in a tissue phantom for 23 min. The dose distribution for a
monoenergetic beam is shown for range comparison.TABLE IV. Summary of the isotopic activities produced and the expected and measured number of total
coincidence events. This activity was produced by a 0.14 nA, 150 MeV proton beam which was pulsed with a
20 s period and implanted into a swine-tissue phantom for 21 min.
Reaction
Expected
activity ~mCi!
by reaction
Expected
activity ~mCi!
by isotope
Expected
counts (3109)
by isotope
Measured
counts (3109)
by isotope
16O(p ,3p4n)10C 5.01 5.01 0.0052
12C(p ,pn)11C 31.83
14N(p ,a)11C 1.57 65.97 3.75 3.0860.04
16O(p ,apn)11C 32.57
14N(p ,pn)13N 2.04 19.94 0.63 1.2560.05
16O(p ,a)13N 17.90
14N(p ,n)14O 0.10 4.05 0.015
16O(p ,pn)14O 3.95
16O(p ,pn)15O 267.65 267.65 1.75 1.8860.02
18O(p ,n)18F 0.0019 0.0019
Totals 362.62 6.15 6.2160.07
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neutrons and other light, energetic charged secondary par-
ticles, including protons and a-particles, are created which
may induce secondary nuclear reactions.20 The production of
positron-emitting isotopes apparently by secondary neutrons
is evident beyond the protons range in Fig. 4. This activity is
almost entirely 14O and is most likely produced by the
16O(n ,3n)14O reaction which has threshold energy of 30.7
MeV. ~Further details on the dose and activity created by
nuclear secondaries may be found in Refs. 20, 35.!
The effects of nuclear interactions on the dose distribution
have been presented by other investigators.20,21 However, the
effect of nuclear secondaries on the activity distribution has
not been reported in detail yet. The radioisotopic images sug-
gest that a library of accurate cross sections over a range of
energies needs to be developed for neutron- and proton-
induced reactions on the elements in tissue.40,43,44 The pres-
ence of activity beyond the proton-beam range suggests that
nuclear reactions induced by secondary neutrons and other
energetic secondary charged particles may produce a signifi-
cant amount of 14O in the treatment volume. However, since
10C, 13N, and 14O are only produced in small quantities, the
uncertainties in their cross sections are of little consequence
to on-line range verification. Most tissues are primarily com-
posed of oxygen, carbon, and hydrogen for which the cross
sections for producing positron-emitting radioisotopes are
reasonably well known. Although the unexpectedly large
production of 14O may have a noticeable effect on the mag-
nitude of images produced on short time scales, due to its
short half-life, it is probably produced from oxygen through
the 16O(p ,p2n)14O and 16O(n ,3n)14O reactions. Thus the
14O distribution primarily reflects the distribution of oxygen
along the beam path.
Unlike 14O, there are no neutron-induced reactions lead-
ing to the production of 13N whose cross sections are large
enough to account for the discrepancies observed. This is
supported by the lack of 13N beyond the range of the proton
beam. Factors which may contribute to the discrepancy in-
clude uncertainties in the cross sections, beam current, and
composition of the tissue.
C. The effects of in vivo biological washout and the
presence of 14O on total dose monitoring
As shown in earlier sections, the number of events de-
tected between pulses n and (n11) varies nearly linearly on
time scales less than about 2 min. While this is true in the
experiments presented here, additional complications will
arise in living tissue. Much of the 15O created will be bound
in water which freely diffuses through cell membranes. This
activity is consequently carried out of the field of view by the
tumor’s vasculature. In this situation, the decay of 15O may
be roughly modeled by two exponential terms.10 The first
term models the nonmobile fraction of the 15O activity which
disappears solely through radioactive decay. The second
term models the mobile fraction of the 15O activity which
disappears through radioactive decay and in vivo biological
washout. The decay constant of the second term depends onMedical Physics, Vol. 26, No. 6, June 1999the half-life of 15O and the average rate of blood flow
through the imaged volume.10 The corresponding half-life
for the washout term may vary greatly depending on the
average blood flow rate. Reported values of the washout
half-life range from roughly 40 s9 to over 3 min.10 If the
treatment volume being imaged has a high blood flow then
the activity will appear to decay on shorter time scales. The
linear approximation of the number of counts detected be-
tween beam pulses will become less accurate making it a less
reliable indicator of dose received in well-perfused treatment
volumes.
It should be noted that a standard water tank, typically
used to verify the range and the dose distribution in many
treatment facilities, is not suitable for calibrating this type of
imaging system. The mechanisms which lead to the transport
of activity within the tank are difficult to quantify accurately
and may vary significantly from calibration to calibration.
Typically, the amount of 15O present is severely underdeter-
mined due to these processes and the amount of 14O is over-
estimated due to the difficulty in quantifying the transport
mechanisms for the mobile component of the 15O. In the
presence of these transport phenomena the 15O radioisotopic
images were observed to be rather strongly peaked at the
distal end of the protons range, much like the Bragg peak.
D. Correlation between the dose distributions and the
induced activity distribution
The change in the total dose deposited in the treatment
volume as a function of time may be monitored fairly reli-
ably in treatment volumes with low blood flow rates. Figure
11 shows that the number of 511 keV gamma-ray pairs de-
tected between beam pulses increases nearly linearly with the
number of beam pulses, and consequently with the dose, for
times less than about 2 min. However, as mentioned earlier,
it is difficult to infer the dose distribution from the activity
distribution since the physical processes leading to the loss
of energy and the creation of positron-emitting nuclei are not
directly related. In the experimental results sections, the end
of the dose distributions were found to coincide rather
closely with the end of the activity distributions as seen in
Figs. 6, 10, and 12. This is primarily due to the 1.2 cm
resolution of the imaging system which is much larger than
the 0.3 cm range of the treatment beam below the
16O(p ,n)15O reactions threshold energy ~Table V!. Since
over 80% of the positron-emitting activity during and shortly
after the treatment is due to the decay of 15O, this will be
true for imaging systems with resolutions down to roughly
0.5 cm.
Figures 9 and 10 show that there are strong correlations
between the radioisotopic activities and the composition of
the tissue. While the extent of the adipose deposit along the
beam path was only one-third the resolution of the imaging
system, the correlations in the 15O and 11C radioisotopic vec-
tors were still significant. Such correlations would be stron-
ger with more extended inhomogeneities or with an imaging
system with better spatial resolution. While the dose depos-
ited in various inhomogeneities may or may not vary signifi-
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topic correlations may be used as reference points for range
verification relative to anatomic features along the beam
path.
The correlations observed in the radioisotopic images of
Figs. 9 and 10 are due to the oxygen content dropping from
75% by mass in tissue to 28% by mass in adipose tissue, and
the carbon content increasing from 11% to 60%, respec-
tively. Equation ~A1! shows that the activity, and conse-
quently the number of decays in any time interval, at any
given depth varies linearly with the number density of target
nuclei. Consequently, if the percent change in the density of
a particular target nuclei is greater than the uncertainty in the
reconstructed radioisotopic images, the compositional varia-
tion should be observable. This condition is common in tis-
sues such as muscle, adipose, and bone, allowing their pres-
ence and location along the beam path to be identified. This
condition is also present for hypoxic versus nonhypoxic tis-
sue but not to the extent that they may be differentiated
based on composition alone. For further discussion on the
detection of hypoxia see Ref. 35.
V. CONCLUSIONS
Based on the results of these experiments it is seen that
on-line range verification may be performed after a single
typical macro-beam pulse with an on-line monitoring sys-
tem. Calculations show that over 80% of the activity created
in such short time scales is 15O, produced by the
16O(p ,pn)15O reaction. The range of the proton beam below
this reaction’s 16.6 MeV threshold energy is 0.3 cm. Since
the best practical resolution for this type of system is very
similar to this residual beam range, the end of the dose dis-
tribution and the activity distribution will coincide to within
the resolution of foreseeable PET imaging systems. The ef-
fects of energy straggling and the momentum spread of the
treatment beam would only be observable by means of the
activity distribution at the end of the range for proton beams
with energies above 150 MeV using an improved imaging
system with a resolution of 2–3 mm.
In general it is very difficult to infer the dose distribution
from the induced activity distribution alone. The total dose
TABLE V. The primary proton-induced reactions in tissue which produce
positron-emitting isotopes.
Reaction
Threshold energy,
lab frame ~MeV!
Q-value
~MeV!
Proton range in
tissue, below
threshold ~cm!
16O(p ,3p4n)10C 39.1 236.8 1.5
12C(p ,pn)11C 20.3 218.7 0.4
14N(p ,a)11C 3.1 22.9 0.02
16O(p ,apn)11C 27.5 225.9 0.8
14N(p ,pn)13N 11.3 210.6 0.2
16O(p ,a)13N 5.5 25.2 0.04
14N(p ,n)14O 6.6 25.9 0.06
16O(p ,p2n)14O 30.7 228.9 0.9
16O(p ,pn)15O 16.6 215.7 0.3
18O(p ,n)18F 2.6 22.4 0.01Medical Physics, Vol. 26, No. 6, June 1999may be monitored more accurately by monitoring the in-
crease in the total number of 511 keV gamma-ray pairs de-
tected between macro-pulses. The number of counts in-
creases roughly linearly for treatment times less than about 2
min, at least in treatment volumes with low blood flow rates.
Variations in the elemental composition along the beam
path are readily observed in layers of distinct tissue types.
Variations as small as about 5% in a single element, aver-
aged over a resolvable region, may be identified. The detect-
able size of these compositional variations will change based
on the uncertainty in the reconstructed isotopic images,
which is determined by the dose delivered and the imaging
time. It may be possible to detect smaller variations if two
isotopic image vectors exhibit strong positive or negative
correlations in the same region. This phenomenon may be
used to verify the range relative to various anatomic features
along the beam path. It may also be particularly useful if
used with high-energy, low-intensity beams in conjunction
with a proton-range telescope45 for transverse patient align-
ment. In this situation, the beam would traverse the pre-
scribed volume at higher energies where the PET isotope
reaction cross sections vary slowly, resulting in more reliable
compositional determination across and beyond the tumor
volume.
Range-verification capability will become increasingly
important for improving dose localization. While it may be
possible to reposition the patient and deliver the prescribed
dose distributions with an uncertainty of just a few millime-
ters, it has been shown that internal organs, such as the pros-
tate, may move 1–3 cm between treatments.46 In such cases,
the advantage of the high dose localization offered by pro-
tons may be compromised or even detrimental without
proper alignment and range verification for the shifting ana-
tomic features.
The prototype on-line PET isotope monitoring system
used for the experiments presented here was designed within
a limited budget with the intention of investigating the fea-
sibility of using PET isotopes as a monitor for proton radio-
therapy beams. It should by no means be considered an op-
timally designed system for clinical use but rather as an
experimental system suitable for initial investigations. To be
clinically useful the solid angle should be increased to de-
crease the imaging time and the resolution should be im-
proved to the subcentimeter range. In addition, rectangular
crystals should be used with no intercrystal shielding, espe-
cially if only one-dimensional decay distributions are being
reconstructed. In this case, depth-of-interaction blurring is
removed by the calibration procedure and the image recon-
struction algorithm. However, blurring will occur if the treat-
ment beam is more than a few centimeters wide.33 Further
design considerations and suggested improvements for on-
line PET isotope monitoring devices may be found in Ref.
33.
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APPENDIX: PRODUCTION OF POSITRON-
EMITTING NUCLEI
A. Nuclear reactions in tissue which produce positron-
emitting isotopes
A small percentage of the particles in a charged-particle
radiotherapy beam will undergo nuclear reactions with ele-
ments in the tissue during treatment. The positron-emitting
isotopes which are produced during proton radiotherapy are
determined by the nuclear isotopic composition of the treated
tissue. The elemental composition of the swine-tissue used
for these experiments are shown in Table I, along with the
composition of human muscle and adipose tissue. The most
abundant elements in tissue from which positron-emitting
isotopes may be produced are oxygen, carbon, and nitrogen.
While positron-emitting isotopes may be produced from
other elements, they are inconsequential due to their low
number density.
The most important reactions in tissue which produce
positron-emitting isotopes are shown in Table V, along with
their threshold energy, Ei
T
, and their Q-value. Also shown is
the residual range of the proton in tissue for proton energies
less than the reaction threshold energies. While the produc-
tion of 10C and 18F are not significant processes, both radio-
isotopes were observed in our experiments and are included
for completeness. Other reactions are discussed in Ref. 35.
The positron-emitting isotopes which may be produced by
protons from the isotopes of oxygen, carbon, and nitrogen
are shown in Table A1 along with their half-lives, t1/2i , their
endpoint energies, and the maximum range of the emitted
positrons in tissue.47
B. Continuous beams
A general treatment of the production and decay of
positron-emitting isotopes by proton radiotherapy beams has
been presented in Ref. 29. Here, a detailed formulation is
presented for analysis of our specific experimental results.
The most important factors in the production of the so-called
PET isotopes are the number of target nuclei per cubic cen-
timeter, ni(r), the particle flux in particles per second per
square centimeter, F(r,t), the beam energy, E(r), at all
points in the treatment volume, and the energy-dependentMedical Physics, Vol. 26, No. 6, June 1999cross sections of the target nuclei for the various PET reac-
tion processes, s ip(E). The energy is expressed in units of
MeV and the cross section is expressed in units of barns
(1 b510224 cm2!.
For a small volume in the treatment field, the time rate of
change in the number, Ni , of positron-emitting nuclei of
type, i, depends on the production rate, by a process, p, and
the decay rate. This is given by
dNip~r,t !
dt 5s ip~E~r!!F~r,t !ni~r!A dz2l iNi~r,t !,
~A1!
where the decay constant of the isotope is l i5ln(2)/t1/2i and
the cross sectional area of the beam is A. If the beam flux is
constant over time, F(r,t)5F(r), with a beam-pulse dura-
tion of Ton seconds, the resultant number of nuclei from the
process is
Nip~r,t !5
Aipmax~r,t !
l i
H ~12e2l lt! if t<Ton~12e2l iTon!e2l i~ l2Ton! if t>Ton,
~A2!
where Aipmax(r,t)5s ip(E(r))F(r)ni(r)A dz is the maximum
activity of isotope, i, that can be produced in a differential
volume through the process, p. The activity, Aip(r,t), is then
given by
Aip~r,t !5l iNip~r,t !
5Aipmax~r,t !H ~12e2l it! if t<Ton~12e2l lTon!e2l i~ t2Ton! if t>Ton,
~A3!
where time is measured from the moment the beam is turned
on. Equation ~A3! may be used to find the distribution of
activity, due to isotope, i, which was created through pro-
cess, p, by a radiotherapy beam with a constant flux over a
period of time, Ton .
C. Macro-pulsed beams
Many of the accelerators used for proton radiotherapy are
synchrotrons which deliver macroscopic pulsed beams due to
the ramp time of the magnets. ~In this treatment we ignore
the microscopic, submicrosecond pulse structure of the beam
due to the rf system.! In these cases the equations above are
only applicable for one macro-pulse of the beam. If the ac-
celerator has a period, T5Ton1Toff , then the activity
TABLE AI. Characteristics of the positron-emitting isotopes produced by
protons incident on isotopes of oxygen, carbon, and nitrogen.
Isotope
Half-life
~s!
b1 endpoint
energy ~MeV!
Maximum b1
range ~cm!
10C 19.3 1.87 0.9
11C 1218 0.96 0.4
13N 598.2 1.19 0.5
14O 70.6 1.81 0.9
15O 122.2 1.72 0.8
18F 6588 0.64 0.3
1004 Litzenberg et al.: On-line monitoring of radiotherapy 1004present at any time is the sum of the activity remaining from
each of the previous pulses. Suppose there are N pulses de-
livered during a treatment. The amount of activity created
through a given process, p, for each pulse is the same as
given in Eq. ~A3!, when t5Ton . Accounting for the decay of
the activity created by each pulse and summing, the activity
present after the last beam pulse is
Aip~r,t !
5Aipmax~r,t !~12e2l iTon!@e2l iT~N21 !!1e2l iT~N22 !)
1fl1e2l iT~N2N !)]
5Aipmax~r,t !~12e2l iTon!
35 (j50
n21
e2 jl lT after n pulses
F (j50
N21
e2 jl iTGe2l i~ t2TN1Toff! if t>~TN2Toff!.
~A4!
In the simplest case, PET activity is created by a continu-
ous beam in a homogenous material of uniform density
through one of the reactions shown in Table V. Generally,
however, the PET activity distribution produced will be the
result of many of these reactions, several of which may pro-
duce the same radioisotope through different reaction pro-
cesses. The final PET activity distribution produced during
the treatment is then the sum of these activity distributions
and is given by
A~r,t !5(
i
(
p
Aip~r,t !. ~A5!
The maximum activity achievable with pulsed beams may
be investigated for radioisotopes with half-lives comparable
to or shorter than the irradiation time. In Eq. ~A4!, if the
number of pulses, n, is very large the series converges so that
Aip~r,t !5Aipmax~r,t !~12e2l iTon! lim
n!`
(j50
n21
e2 jl iT
5Aipmax~r! for t@T . ~A6!
Isotopes whose half-lives are short compared to the irradia-
tion time will approach an equilibrium activity level as the
decay rate approaches the production rate.
D. The particle flux throughout the treatment volume
The particle flux term, F(r,E ,t), in the equations above
describes the particle flux, energy, and energy distribution at
all points in the treatment volume. The model of the energy
and flux distributions is similar to other models.29 To calcu-
late the distribution of positron-emitting activity, the energy
as a function of depth must be determined for the material of
interest. This is accomplished by numerically integrating the
inverse of the total stopping power48 as follows, where Eo is
the initial beam energy and z is the depth at which the beam
has energy E:Medical Physics, Vol. 26, No. 6, June 1999z5E
E
EoS dEdx D T
21
dE . ~A7!
In addition to knowing the range-energy relationship it is
also necessary to know the range number-distance curve.
Particle flux is primarily lost through nonelastic nuclear in-
teractions. At 250 MeV and 150 MeV approximately 31%
and 17%, respectively, of the protons passing through tissue
are removed from the beam by nuclear processes.48 By com-
parison, our calculations for 150 MeV protons in tissue show
that about 3.5% of the beam flux produces positron-emitting
isotopes through the reactions shown in Table V. It has been
shown29 that if Pabs(E) is the probability that a particle is
absorbed and undergoes a nuclear reaction before the end of
its range, the fraction of the initial flux, r
abs
Eo (z), remaining at
a given depth is
r
abs
Eo ~z !5
@12Pabs~Eo!#
@12Pabs~E~z !!#
, ~A8!
where E(z) is the beam energy as a function of depth. The
resulting proton flux drops off with increasing depth as
F~z !5Forabs
Eo ~z !, ~A9!
where Fo is the initial proton flux.
E. Cross sections for producing positron-emitting
isotopes
Cross sections for the reactions listed in Table V are pre-
sented in Figs. 2~a! and 2~b!.32,39,40,48–53 Due to the high
number density of oxygen in tissue and the relatively high
cross section for the 16O(p ,pn)15O reaction, 15O is the most
active isotope at the end of a typical treatment. Despite the
relatively low number density of 12C in tissue, a significant
amount of 11C activity is also produced by the ~p,pn! and
(p ,pna) reactions due to the high production cross section
on 12C and the abundance of 16O. As noted earlier, the
threshold energies, as measured in the reference frame of the
lab, vary from 2.6 to 39.1 MeV, below which the production
goes to zero. The endpoint of the proton’s range is therefore
slightly beyond the distal end of the activity distribution as
given in Table V. Consequently, the end of the activity dis-
tribution and the end of the proton’s range will not occur at
the same depth. It is shown in Table II that over 80% of the
positron-emitting activity imaged on short time scales is due
to the decay of 15O. The range of the treatment beam below
the reaction threshold for the 16O(p ,pn)15O reaction is only
0.3 cm. Thus for on-line imaging, the end of the 15O activity
distribution provides the best marker for the range of the
treatment beam.
F. Correlation between total dose and total activity
The possibility of discerning the dose distribution from
the nuclear decay distribution of long-lived positron-emitting
activity created by the treatment beam has previously been
explored by other investigators.27,29 Because the physical
mechanisms by which nuclear and atomic interactions occur
1005 Litzenberg et al.: On-line monitoring of radiotherapy 1005are not related, it is difficult to extract the dose distribution
from the nuclear decay distribution. This has been demon-
strated with 11C decay distributions produced by proton
beams in Lucite.29 It is possible, however, to monitor the
integrated dose delivered by monitoring the total number of
annihilation events detected as a function of time. The total
dose delivered after n pulses is given by
D5
energy
mass
5
Pbeamt
rTV
5
EoFo~nTon!
rTV
, ~A10!
where Pbeam5EoFo is the power delivered by the beam. The
units of the dose are in Gray if the beam energy is in MeV,
the beam current, Fo , is in microamps, Ton is in seconds,
and the mass of the treated volume is in kilograms. The total
activity present after n pulses is given by integrating Eq.
~A5! over the treatment volume. After performing the inte-
gral and solving for the initial beam current, the total dose
after n pulses, D(n), is found to be related to the activity by
the relationship
D~n !5
Eon
rTV
Nn
( i(p@Y ip( j50
n21e2 jl iT#
. ~A11!
Here, Nn5A(t)Ton5A(t)Toff is the number of decays be-
tween beam pulses n and (n11), and
Y ip5~12e2l iTon!E
0
R
s ip~E~z !!rabs
Eo ~z !ni~z !A dz ~A12!
is the yield of radioisotope, i, by the process, p, per
~proton/cm2! per pulse.
The number of decays between successive beam pulses
will eventually become constant if the treatment time is long
compared to the half-life of the most significant, longest-
lived isotope, which is typically 11C. However, if the treat-
ment time is less than or comparable to the half-life of the
shortest-lived isotope, the number of decays detected be-
tween each beam pulse will be approximately linear with
dose. Clinical treatment times are typically less than 2 min,
or less than one half-life of 15O which is the shortest-lived
isotope produced in abundance. In Fig. 11 it is shown that on
short time scales the number of decay events detected be-
tween beam pulses increases roughly linearly with the treat-
ment time for macro-pulsed beams. Consequently, it is pos-
sible, within certain limitations, to monitor the integrated
dose delivered by monitoring the total number of annihila-
tion events detected between beam pulses.
G. Activity and dose calculations
A simulation code was written to estimate the depth-
distribution of PET isotopes produced by proton beams in
materials of varying composition. Several layers of materials
of differing composition may be placed in series. The stop-
ping power of the material is
1
rT
S dEdz D T5(i
1
r i
S dEdz D i , ~A13!
Medical Physics, Vol. 26, No. 6, June 1999where (dE/dz) i is the stopping power of the individual ele-
ments. Stopping power values are obtained from spline fits to
the values given in relevant data compilations.48 The dose
and energy as a function of depth are then found by numeri-
cally integrating Eq. ~A13!. Once the energy as a function of
depth, E(z), is known the energy-dependent PET-isotope
production cross sections may be mapped into depth-
dependent cross sections. The depth-dependent particle flux
is calculated from Eq. ~A8!. Range straggling and scattering
have not been implemented in the code. The isotopic distri-
bution of PET activity is then calculated in 0.2 cm incre-
ments with Eq. ~A5! using Eq. ~A3! for continuous beams
and Eq. ~A4! for pulsed beams. The total and isotopic activ-
ity distributions may be integrated over the experimental im-
aging time and compared directly with experimental results.
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